Back to top
more

Better trading starts here.

Brokerage Reports

Research for DMAC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

DiaMedica Therapeutics, Inc. [DMAC]

Reports for Purchase

Showing records 1 - 19 ( 19 total )

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

08/11/2022

Company Report

Pages: 5

2Q22 Results

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 5.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

08/11/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

07/07/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

07/06/2022

Company Report

Pages: 4

Pause in Stroke Trial

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 5.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/05/2022

Company Report

Pages: 5

1Q22 Results, Lowering Target

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 5.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

05/05/2022

Daily Note

Pages: 7

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for DMAC

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

09/27/2021

Company Report

Pages: 5

Financing Overhang Removed

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/14/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

09/13/2021

Company Report

Pages: 4

Stroke Trial Begins

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/12/2021

Company Report

Pages: 5

2Q21 Results

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

06/30/2021

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

06/29/2021

Company Report

Pages: 4

Early Kidney Disease Data

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

05/06/2021

Company Report

Pages: 5

1Q21 Results

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/11/2021

Company Report

Pages: 5

4Q20 Results - Kidney Indications in Focus

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/11/2021

Daily Note

Pages: 5

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

02/17/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

02/17/2021

Company Report

Pages: 46

First Win in 25 Years? - Initiating Coverage

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 100.00

Research Provided by a Third Party

Company: DiaMedica Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/18/2020

Daily Note

Pages: 3

Healthcare- Join our Call Today at 11AM to Unlock the Potential of DM199 in CKD and Stroke

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party